Lindsey R Enewold, Ph.D.

Background:

The SEER database collects data about people with cancer. SEER stands for Surveillance, Epidemiology, and End Results. Medicaid is a kind of health insurance. It is for people who have low income or serious medical needs. Many studies have shown that Medicaid recipients with cancer are more likely to be diagnosed later in the disease than people with other insurance. They are also less likely to get treatment. Researchers want to compare Medicaid data and SEER data. They want to make this available to other scientists.

Objectives:

To link people in the SEER database to Medicaid data for the years around their cancer diagnosis. To create a file that contains SEER case numbers linked to Medicaid numbers.

Eligibility:

No people are enrolled in this study.

Design:

The SEER finder file will be securely uploaded to the CMS Data Center.

The finder file will be matched against the Medicaid Personal Summary file at the CMS Data Center.

If participants appear in both the SEER file and Medicaid file, their data will be extracted.

The dates of Medicaid data will be compared with the SEER date of diagnosis. Researchers will see if the Medicaid dates fall in certain periods. These are 12 months before, the month of, and 11 months after diagnosis.

If participants are eligible for Medicaid for these periods, a flag will be created in the file. It will note the participants is eligible and why.

The SEER finder file will be destroyed.

The only data saved will be:

Each participant's unique random SEER case number linked to their Medicaid number

Monthly flags about Medicaid eligibility

Numerous studies have demonstrated that Medicaid recipients with cancer are more likely to be diagnosed at an advance stage and less likely to receive recommended treatment than are patients with other types of health insurance. The objective of this project is to link persons included in the Surveillance, Epidemiology and End Results (SEER) data to Medicaid enrollment information during the year before and after their cancer diagnosis. NCI is also seeking permission to create and maintain a file that crosswalks each patient's SEER case number to their Medicaid enrollment number. Information about Medicaid enrollment would be available by special request to all researchers who want to use SEER data to assess the impact of Medicaid enrollment on stage and treatment.

Linkage of Medicaid Enrollment Information to Surveillance, Epidemiology and End Results Data

Linkage of Medicaid Enrollment Lnformation to Surveillance, Epidemiology and End Results Data

National Cancer Institute (NCI)

Neoplasms

Digestive System Diseases

All Conditions

Blood and Lymph Conditions

Immune System Diseases

Infections

Symptoms and General Pathology

Rare Diseases

Stomach Neoplasms

Carcinoma

Carcinoma, Hepatocellular

Lymphoma

Neuroendocrine Tumors

Burkitt Lymphoma

Hepatoblastoma

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Neoplasms by Histologic Type

Communicable Diseases

Epstein-Barr Virus Infections

Virus Diseases

Herpesviridae Infections

DNA Virus Infections

Tumor Virus Infections

Lymphoma, B-Cell

Lymphoma, Non-Hodgkin

Lymphoproliferative Disorders

Lymphatic Diseases

Immunoproliferative Disorders

Neuroectodermal Tumors

Neuroectodermal Tumors, Primitive

Neoplasms, Germ Cell and Embryonal

Neoplasms, Nerve Tissue

Stomach Cancer

Lymphosarcoma

Neuroendocrine Tumor

B-cell Lymphoma

Neuroepithelioma

Patients aged 0-17 years at primary gastrointestinal cancer diagnosis

Patients aged 18-24 years at primary gastrointestinal cancer diagnosis

Paul G. Kemps, MD

The goal of this observational population-based cohort study is to investigate the clinical characteristics and outcomes of children and adolescents with primary gastrointestinal malignancies registered in the publicly available Surveillance, Epidemiology, and End Results (SEER) 17 database during 2000-2019.

The investigators aim to describe the patient and tumor characteristics, treatments, and outcomes of children and adolescents diagnosed with primary gastrointestinal malignancies, and to analyze these data for trends over time. In addition, the investigators want to explore independent prognostic factors for overall survival. Finally, the investigators want to describe subsequent primary malignancies diagnosed among patients from the study cohort, as well as to calculate their risk of developing a second primary cancer relative to the general population. Data on children (aged 0-17 years at diagnosis) and young people aged 18-24 years at diagnosis are analyzed separately. Special focus is laid on patients with primary carcinomas of the gastrointestinal tract; particularly colorectal carcinoma.

GastroIntestinal Cancer in Children and Adolescents

GastroIntestinal Cancer in Children and Adolescents (GICCA): a SEER Population-based Study

Data are publicly available through SEER under the SEER Research Data Use Agreement.

Defined as the time between the date of diagnosis and the date of death from any cause (event) or date of last follow-up.

Standardized incidence of second primary malignancies in patients who survived (i) two or more months, or (ii) five or more years after initial gastrointestinal cancer diagnosis, relative to the general population.

Juliana Children's Hospital

Researcher

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Linkage of Medicaid Enrollment Information to Surveillance, Epidemiology and End Results Data	NCT02875327	Neoplasm Health Services... Outcome Assessm... Healthcare Disp...		1 Year - 120 Years	National Institutes of Health Clinical Center (CC)
GastroIntestinal Cancer in Children and Adolescents	NCT05693519	Gastrointestina... Colorectal Canc... Gastric Cancer Hepatoblastoma Hepatocellular ... Burkitt Lymphom... Neuroendocrine ...		0 Years - 24 Years	Leiden University Medical Center

Spots Global Cancer Trial Database for seer

Every month we try and update this database with for seer cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for seer

Every month we try and update this database with for seer cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for seer cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.